Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Other financing activities: 2021-2025

Historic Other financing activities for C4 Therapeutics (CCCC) over the last 3 years, with Sep 2025 value amounting to $164,000.

  • C4 Therapeutics' Other financing activities fell 44.78% to $164,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $571,000, marking a year-over-year decrease of 11.20%. This contributed to the annual value of $382,000 for FY2024, which is 3.80% up from last year.
  • Latest data reveals that C4 Therapeutics reported Other financing activities of $164,000 as of Q3 2025, which was up 50.46% from $109,000 recorded in Q1 2025.
  • In the past 5 years, C4 Therapeutics' Other financing activities ranged from a high of $297,000 in Q3 2024 and a low of -$286,000 during Q4 2021.
  • Its 3-year average for Other financing activities is $113,667, with a median of $104,000 in 2023.
  • As far as peak fluctuations go, C4 Therapeutics' Other financing activities soared by 7,433.33% in 2022, and later tumbled by 52.73% in 2023.
  • Quarterly analysis of 5 years shows C4 Therapeutics' Other financing activities stood at -$286,000 in 2021, then dropped by 16.67% to $150,000 in 2022, then spiked by 75.33% to -$1,000 in 2023, then soared by 200.00% to $1,000 in 2024, then tumbled by 44.78% to $164,000 in 2025.
  • Its Other financing activities stands at $164,000 for Q3 2025, versus $109,000 for Q1 2025 and $1,000 for Q4 2024.